Ardelyx reports 19% Q3 revenue growth, reaffirms 2026 guidance and completes Phase‑3 trial enrollment
Ardelyx Inc. posted third‑quarter 2026 product revenue of $125.5 million, a 19% year‑over‑year increase, driven by IBSRELA sales of $96.3 million (up 23%) and XPHOZAH sales of $29.2 million (up 7%). The company reiterated its full‑year 2026 revenue guidance of $350‑$370 million for IBSRELA and $110‑$120 million for XPHOZAH, and said it expects to achieve profitability in 2027. It also announced that enrollment in its ACCEL Phase III trial for chronic idiopathic constipation was completed ahead of schedule.
Why it matters
The reaffirmed guidance signals that Ardelyx expects its revenue trajectory to remain on target, supporting investor confidence in future cash flows. The ahead‑of‑schedule trial enrollment reduces clinical‑development risk and may accelerate a potential new indication, while the cash balance of $285.3 million provides runway for continued growth and profitability efforts (the company said).
Key facts
- 1Q3 2026 product revenue was $125.5 million, up 19% YoY. stocktitan.net
- 2IBSRELA generated $96.3 million in Q3 2026, a 23% YoY increase. stocktitan.net
- 3XPHOZAH generated $29.2 million in Q3 2026, a 7% YoY increase. finance.yahoo.com
- 4Full‑year 2026 IBSRELA revenue guidance is $350‑$370 million. stocktitan.net
- 5Full‑year 2026 XPHOZAH revenue guidance is $110‑$120 million. stocktitan.net
- 6Cash and short‑term investments totaled $285.3 million as of September 30 2026. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.